Citation Impact
Citing Papers
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine
2009
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
2007 StandoutScience
Macrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression
2016
MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo
2010 Standout
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
2012 Standout
Interferons and Apoptosis
2003
Bifluoride Ion Mediated SuFEx Trifluoromethylation of Sulfonyl Fluorides and Iminosulfur Oxydifluorides
2019 StandoutNobel
Mechanisms of Endocrine Resistance in Breast Cancer
2010
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial
2013
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
2009
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
2007 Nature
Targeting HER proteins in cancer therapy and the role of the non-target HER3
2007
Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer
2007
Herceptin: mechanisms of action and resistance
2005
Hallmarks of Cancer: The Next Generation
2011 Standout
Antitumor activity of HER-2 inhibitors
2004
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
2013 Standout
The role of HER2 in cancer therapy and targeted drug delivery
2010
BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib
2012
Synergistic Inhibition with a Dual Epidermal Growth Factor Receptor/HER-2/neu Tyrosine Kinase Inhibitor and a Disintegrin and Metalloprotease Inhibitor
2008
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
2006 Standout
ErbB receptors and signaling pathways in cancer
2009
Synthetic Affibody Molecules: A Novel Class of Affinity Ligands for Molecular Imaging of HER2-Expressing Malignant Tumors
2007
Identification of a subpopulation of metastatic breast cancer patients with very high HER2 expression levels and possible resistance to trastuzumab
2011
EGFR Antagonists in Cancer Treatment
2008 Standout
Breast cancer
2016 Standout
The multifaceted roles of glycogen synthase kinase 3β in cellular signaling
2001 Standout
Oncogene addiction: setting the stage for molecularly targeted cancer therapy
2007
Geldanamycin Restores a Defective Heat Shock Responsein Vivo
2001
Comparing antibody and small-molecule therapies for cancer
2006
Proteasome inhibition leads to the activation of all members of the heat‐shock‐factor family
1998
Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer
2003
Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer
2008
Cell Signaling by Receptor Tyrosine Kinases
2010 Standout
Hsp90 as a capacitor for morphological evolution
1998 StandoutNature
Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer
2006
Cancer drug resistance: an evolving paradigm
2013 Standout
Trastuzumab: triumphs and tribulations
2007
The HER family and cancer: emerging molecular mechanisms and therapeutic targets
2007
Drug-Induced Hepatotoxicity
2003 Standout
The Nuclear Ubiquitin-Proteasome System Degrades MyoD
2001 StandoutNobel
EGF–ERBB signalling: towards the systems level
2006 Standout
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
2005 Standout
Protein aggregation and neurodegenerative disease
2004 Standout
Targeting the function of the HER2 oncogene in human cancer therapeutics
2007
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
Matrix Metalloproteinases: Regulators of the Tumor Microenvironment
2010 Standout
Mitochondrion-mediated apoptosis in HIV-1 infection
2003
Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy
2009
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
The causes and consequences of genetic heterogeneity in cancer evolution
2013 StandoutNature
Host defense, viruses and apoptosis
2001
Cancer immunotherapy comes of age
2011 StandoutNature
β-Arrestin–mediated β1-adrenergic receptor transactivation of the EGFR confers cardioprotection
2007 StandoutNobel
Interferons α and λ Inhibit Hepatitis C Virus Replication With Distinct Signal Transduction and Gene Regulation Kinetics
2006 StandoutNobel
AKT/PKB Signaling: Navigating the Network
2017 Standout
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
2010 Standout
Clinical pharmacokinetics of tyrosine kinase inhibitors
2009
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
2011 Standout
The PI3K Pathway in Human Disease
2017 Standout
Exploration of 1-(3-chloro-4-(4-oxo-4H-chromen-2-yl)phenyl)-3-phenylurea derivatives as selective dual inhibitors of Raf1 and JNK1 kinases for anti-tumor treatment
2012
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
2005 Standout
Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling
2009 Standout
Cervical cancer
2019 Standout
AMPK: a nutrient and energy sensor that maintains energy homeostasis
2012 Standout
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer
2007 Standout
Gene regulation by long non-coding RNAs and its biological functions
2020 Standout
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
2010
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
2015 Standout
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
Monofluorination of Organic Compounds: 10 Years of Innovation
2015 Standout
3d Transition Metals for C–H Activation
2018 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
The Pathophysiology of Mitochondrial Cell Death
2004 StandoutScience
Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease
2010 Standout
Rapid and reversible relocalization of heat shock factor 1 within seconds to nuclear stress granules
1999
Trastuzumab in the management of early and advanced stage breast cancer.
2007
Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy
2010
Gefitinib Induces Apoptosis in the EGFRL858R Non–Small-Cell Lung Cancer Cell Line H3255
2004
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Cardiac Toxicity and Efficacy of Trastuzumab Combined with Pertuzumab in Patients with Trastuzumab-Insensitive Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
2008
Chromone: A Valid Scaffold in Medicinal Chemistry
2014 Standout
Functional Nanomaterials for Phototherapies of Cancer
2014 Standout
Complementary regulation of TBC1D1 and AS160 by growth factors, insulin and AMPK activators
2007
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
Adjuvant Therapy in Patients With Resected Poor-Risk Head and Neck Cancer
2006
Drug–Induced Liver Injury: Mechanisms and Test Systems
2001
Roles for Growth Factors in Cancer Progression
2010
Inhibition of HIV-1 Infection by Small Interfering RNA-Mediated RNA Interference
2002 StandoutNobel
Compact Biocompatible Quantum Dots Functionalized for Cellular Imaging
2008 StandoutNobel
CF2H, a Hydrogen Bond Donor
2017 Standout
HSP90 Interacts with and Regulates the Activity of Heat Shock Factor 1 in Xenopus Oocytes
1998
Photopharmacology: Beyond Proof of Principle
2014 StandoutNobel
Works of Wenle Xia being referenced
Regulation of Survivin by ErbB2 Signaling: Therapeutic Implications for ErbB2-Overexpressing Breast Cancers
2006
Acquired Resistance to Small Molecule ErbB2 Tyrosine Kinase Inhibitors
2008
Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016
2004
Lapatinib Antitumor Activity Is Not Dependent upon Phosphatase and Tensin Homologue Deleted on Chromosome 10 in ErbB2-Overexpressing Breast Cancers
2007
HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors
2007
Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways
2002
Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells
2007
A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer
2006
Study of the Biologic Effects of Lapatinib, a Reversible Inhibitor of ErbB1 and ErbB2 Tyrosine Kinases, on Tumor Growth and Survival Pathways in Patients With Advanced Malignancies
2005
Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells
2005
Transcriptional Activation of Heat Shock Factor HSF1 Probed by Phosphopeptide Analysis of Factor 32P-labeled in Vivo
1998
Hyperphosphorylation of Heat Shock Transcription Factor 1 Is Correlated with Transcriptional Competence and Slow Dissociation of Active Factor Trimers
1997
Azidothymidine and interferon-alpha induce apoptosis in herpesvirus-associated lymphomas.
1999
Modulation of tolerance by mutant heat shock transcription factors.
1999